在过去的10年里,铂类抗癌药物取得了重要的进展,又有4种新药,奈达铂、奥沙利铂、舒铂和洛铂相继于1995～2001年成功上市,同时也有多个候选药物因疗效低、毒性大,与顺铂、卡铂比较无优势而在临床试验中被淘汰.目前还有另外9种铂化合物仍在进行临床研究,这些化合物为顺铂和卡铂的类似物、亲脂性配合物、口服铂(Ⅳ)配合物、多核铂配合物以及具有空间位阻的铂配合物.新的铂类抗癌药将在今后10～20年内从那些在临床研究中显示出低毒性、抗癌谱广、与现有药物无交叉耐药性的化合物中产生.
参考文献
| [1] | 李以欣 .癌症化学治疗的首选药物[J].国外医药(合成药、生化药、制剂分册),1998,19(02):89-101. |
| [2] | 张伦.铂类抗癌药物市场分析[J].中国药房,2003(03):138-140. |
| [3] | Ernest Wong;Christen M G .Current status of platinum-based antitumor drugs[J].Chemical Reviews,1999,99:2451-2466. |
| [4] | 刘伟平,高文桂,普绍平,谌喜珠,何键,杨一昆.治疗癌症的铂族金属配合物[J].药学进展,2001(01):27-31. |
| [5] | 王联红;尤启冬;苟少华 .抗肿瘤铂类配合物的研究进展[J].药物化学进展,2003,2:161-187. |
| [6] | Kelland L R;Clarke S J;Mckeage M J .Advances in platinum complex cancer chemotherapy[J].Platinum Metals Review,1992,36(04):178-191. |
| [7] | 刘伟平,杨一昆,熊惠周.铂类抗癌配合物构效关系的理论探讨[J].贵金属,1995(02):10-14,18. |
| [8] | Bagrova S G .Results of phase Ⅱ clinical trials of cycloplatam in refractory solid tumors[J].Voprosy Onkologii,2001,47(06):752-756. |
| [9] | Saito T;Manabe Y;Saito H .Ototoxicity of the new platinum anticancer agent TRK-710 in comparison with cisplatin[J].Journal of for Oto-Rhino-Laryngology and its Related Specialties,1995,57(05):235-255. |
| [10] | Maclean D S;Khokhar A R;Perez-Soler R .NDDP, a liposomal platinum antitumor agent[J].Cancer Biotherapy and Radiopharmaceuticals,2000,15(03):253-259. |
| [11] | Kishimoto S;Miyazawa K;Terakawa Y;Ashikari H;Ohtani A;Fukushima S;Takeuchi Y .Cytotoxicity of cis-(((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato))-platinum (II) suspended in Lipiodol in a newly established cisplatin-resistant rat hepatoma cell line.[J].Japanese Journal of Cancer Research,2000(12):1326-1332. |
| [12] | 普绍平,高文桂,余尧,刘祝东,刘伟平,杨一昆.新型铂族金属抗肿瘤药物赛特铂的研究现状[J].贵金属,2002(04):53-57. |
| [13] | Lee YA.;Kim KM.;Lee CO.;Sohn YS.;Lee SS. .Synthesis and oral antitumor activity of tetrakis (carboxylato)platinum(IV) complexes[J].Journal of Medicinal Chemistry,2000(7):1409-1412. |
| [14] | Respondek J;Engel J .Organometallics in Medicine[J].Drugs of the Future,1996,21(04):391-408. |
| [15] | Brabe V;Kasparkova J .DNA modification by a novel bifunctional trinuclear platinum antitumor agent[J].Biochemistry(Moscow),1999,38(21):6781-6790. |
| [16] | Holford J;Raynaud F;Murrer BA;Grimaldi K;Hartley JA;Abrams M;Kelland LR .Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-(amminedichloro(2-methylpyridine)) platinum(II) (AMD473).[J].Anti-Cancer Drug Design,1998(1):1-18. |
| [17] | Raynaud F I;Boxall F E;Goddard P M .Cis-dichloro amine/2-methylpridine platinum(Ⅱ), a novel sterically hindered platinum complexes[J].Clinical Cancer Research,1997,3(11):2063-2067. |
| [18] | Hay M P .ZDO473 astra zeneca[J].Current Opinion in Investigational Drugs,2000,1(10):263-269(Ⅳ. |
上一张
下一张
上一张
下一张
计量
- 下载量()
- 访问量()
文章评分
- 您的评分：
-
10%
-
20%
-
30%
-
40%
-
50%